I. CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claims 1-7 (cancelled)

Claim 8 (not entered): A method for the treatment of retina or optic nerve head neuropathy associated with glaucoma which comprises administering to a mammal a composition comprising an effective amount of one or more non-peptide neurotrophic factor stimulator(s) and a pharmaceutically acceptable vehicle, wherein the non-peptide neurotrophic factor stimulator is selected from the group consisting of: AIT-082 (neotrofin), ONO-2506, CB-1093, NS521 ((1-(1-butyl)-4-(2-oxo-1-benzimidazolone) piperidine, SS-701, KT-711 and clenbuterol, and wherein said composition is administered topically or intraocularly.

Claim 9 (canceled)

Claim 10 (not entered): A method according to claim ~~9~~ 8, wherein the neurotrophic factor stimulator is AIT-082 (neotrofin).

Claims 11-14 (cancelled)

Claim 15 (not entered): The method of claim 8, wherein the composition is administered by intraocular injection prior to ocular surgery.

Claim 16 (previously presented): The method of claim 8, wherein the composition is administered by intraocular injection during ocular surgery.

Claim 17 (previously presented): The method of claim 8, wherein the composition is administered by intraocular injection prior to and during ocular surgery.

Claim 18 (previously presented): The method of claim 15, wherein the composition is a balanced salt irrigating solution.

Claim 19 (previously presented): The method of claim 16, wherein the composition is a

balanced salt irrigating solution.

Claim 20 (previously presented): The method of claim 17, wherein the composition is a balanced salt irrigating solution.

Claim 21 (previously presented): The method of claim 15, wherein the composition is administered through retrobulbar or periocular injection.

Claim 22 (withdrawn): A method for treatment of a disorder of the outer retina selected from the group consisting of acute retinopathies associated with trauma, post-surgical complications, damage associated with ocular laser therapy including photodynamic therapy (PDT), surgical light induced iatrogenic retinopathy, age related macular degeneration and retinal ischemia, said method comprising administering to a mammal a composition comprising an effective amount of one or more neurotrophic factor stimulator(s) and a pharmaceutically acceptable vehicle.

Claim 23 (withdrawn): The method of claim 22, wherein the neurotrophic factor stimulator is selected from the group consisting of: AIT-082 (neotrofin), idebenone, ONO-2506, CB-1093, NS521 ((1-(1-butyl)-4-(2-oxo-1-benzimidazolone) piperidine, SS-701, KT-711 and clenbuterol.

Claim 24 (withdrawn): The method of claim 23, wherein the neurotrophic factor stimulator is AIT-082 (neotrofin).

Claim 25 (withdrawn): The method of claim 22, wherein the composition is an oral formulation.

Claim 26 (withdrawn): The method of claim 22, wherein the composition is a topical ophthalmic, or intraocular formulation.

A. Conclusion

This is submitted to be a complete response to the outstanding Notice of Non-Compliant Amendment. Based on the foregoing arguments, the claims are believed to be in condition for allowance; a notice of allowability is therefore respectfully requested.

The Examiner is invited to contact the undersigned attorney at (817) 551-4321 with any questions, comments or suggestions relating to the referenced patent application.

Respectfully submitted,

Teresa J. Schultz
Reg. No. 40,526
Attorney for Applicants

ALCON RESEARCH, LTD.
6201 S. Freeway, Q-148
Fort Worth, TX 76134-2099
(817) 551-4321

Date: 29 October 2004